Atrion (NASDAQ:ATRI) reported $48.90 million in sales this quarter. This is a 14.54 percent increase over sales of $42.69 million the same period last year.
Orchard Therapeutics Announces Clinical And Preclinical Data In Programs Targeting Neurometabolic And CNS Disorders At ASGCT
New OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with MPS-IH including normal growth rates, improvement in joint function and progressive acquisition of
